Mazindol

drug

On this page

Also known as AN-448MagrilonMazanorMazildeneMazindol civSAH-42548SanorexTerenacTeronacmazindole

Summary

Mazindol (CHEMBL781) is an approved small molecule (ATC A08AA05) targeting SLC6A2; indicated across 5 conditions including obesity disorder and attention deficit-hyperactivity disorder.

At a glance

Status: Approved (max clinical phase 4)
Modality: Small molecule
ATC class: A08AA05
Targets: 1 (SLC6A2)
Indications: 5 conditions
Clinical trials: 3
Chemistry: 284.74 Da · C16H13ClN2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL781
Name	Mazindol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4020
ATC	A08AA05
Molecular formula	C16H13ClN2O
Molecular weight	284.74
InChIKey	ZPXSCAKFGYXMGA-UHFFFAOYSA-N

SMILES: C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O

IUPAC name: 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol

Also known as: AN-448, Magrilon, Mazanor, Mazildene, Mazindol, Mazindol civ, SAH-42548, Sanorex, Terenac, Teronac, mazindol, mazindole

Patent coverage: 4,014 distinct patent families (16,446 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 16,358 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC6A2	NET	Inhibition	9.3	0.4%	P23975

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Endothelin receptor type B, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Histamine H1 receptor, Mu-type opioid receptor, Sodium-dependent dopamine transporter, Adenosine receptor A3, Sodium-dependent dopamine transporter, Sigma non-opioid intracellular receptor 1, Sodium-dependent serotonin transporter, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 53 potent at pChembl ≥ 5 of 55 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A2	9.04	IC50	0.92	nM	CHEMBL_ACT_18050334
SLC6A2	8.31	IC50	4.9	nM	CHEMBL_ACT_393947
P23977	8.15	IC50	7	nM	CHEMBL_ACT_325834
P23977	8.09	IC50	8.1	nM	CHEMBL_ACT_346195
P23977	8.09	IC50	8.1	nM	CHEMBL_ACT_393940
P23977	8.09	IC50	8.1	nM	CHEMBL_ACT_45883
P23977	8.08	IC50	8.4	nM	CHEMBL_ACT_346196
P23977	8.06	Kd	8.63	nM	CHEMBL_ACT_794002
P23977	8.05	IC50	9	nM	CHEMBL_ACT_325831
SLC6A2	7.95	Ki	11.3	nM	CHEMBL_ACT_18050411
SLC6A3	7.89	IC50	13	nM	CHEMBL_ACT_18050278
Q61327	7.89	IC50	13	nM	CHEMBL_ACT_18050398
P23977	7.89	IC50	13	nM	CHEMBL_ACT_325835
P23977	7.89	IC50	12.94	nM	CHEMBL_ACT_432192
SLC6A2	7.87	Ki	13.5	nM	CHEMBL_ACT_18050414
P23977	7.85	IC50	14	nM	CHEMBL_ACT_325832
SLC6A2	7.75	Ki	18	nM	CHEMBL_ACT_393944
SLC6A2	7.75	Ki	18	nM	CHEMBL_ACT_432195
SLC6A3	7.66	IC50	22	nM	CHEMBL_ACT_2522824
SLC6A3	7.66	IC50	22.1	nM	CHEMBL_ACT_2587195
SLC6A3	7.66	Ki	22.1	nM	CHEMBL_ACT_2699944
SLC6A3	7.66	IC50	22.1	nM	CHEMBL_ACT_3285125
SLC6A3	7.66	Ki	22.1	nM	CHEMBL_ACT_3303766
SLC6A3	7.66	Ki	22.1	nM	CHEMBL_ACT_6357265
SLC6A2	7.57	AC50	27	nM	CHEMBL_ACT_25145016
P23977	7.5	Ki	32	nM	CHEMBL_ACT_1106053
SLC6A3	7.46	Ki	34.6	nM	CHEMBL_ACT_18050406
P23977	7.38	Ki	41.6	nM	CHEMBL_ACT_1106052
P23977	7.37	IC50	42.6	nM	CHEMBL_ACT_346198
SLC6A3	7.37	IC50	42.6	nM	CHEMBL_ACT_393941
SLC6A3	7.37	IC50	43	nM	CHEMBL_ACT_393945
SLC6A3	7.37	IC50	42.6	nM	CHEMBL_ACT_432191
SLC6A4	7.35	Ki	45	nM	CHEMBL_ACT_18050456
SLC6A3	7.35	Ki	45	nM	CHEMBL_ACT_393942
SLC6A3	7.35	Ki	45	nM	CHEMBL_ACT_432193
P23977	7.35	Ki	44.3	nM	CHEMBL_ACT_436179
SLC6A4	7.3	Ki	50	nM	CHEMBL_ACT_393943
SLC6A4	7.3	Ki	50	nM	CHEMBL_ACT_432194
SLC6A4	7.27	IC50	54	nM	CHEMBL_ACT_18050381
SLC6A3	7.13	Ki	74.2	nM	CHEMBL_ACT_18050409
P23977	7.11	IC50	77	nM	CHEMBL_ACT_325836
P23977	7.07	IC50	85	nM	CHEMBL_ACT_325837
SLC6A4	7.03	IC50	94	nM	CHEMBL_ACT_393946
SLC6A3	7	AC50	100	nM	CHEMBL_ACT_25123966
SLC6A4	6.87	Ki	136	nM	CHEMBL_ACT_18050435
SLC6A4	6.64	AC50	230	nM	CHEMBL_ACT_25150349
P31652	6.64	IC50	231	nM	CHEMBL_ACT_346199
SIGMAR1	6.63	IC50	234.4	nM	CHEMBL_ACT_1150129
P31652	6.61	Ki	247.5	nM	CHEMBL_ACT_436177
P23977	6.54	IC50	290	nM	CHEMBL_ACT_325833
Q61327	6.39	Ki	404	nM	CHEMBL_ACT_18050404
HRH1	5.12	AC50	7500	nM	CHEMBL_ACT_25212526
ADORA3	5.02	AC50	9600	nM	CHEMBL_ACT_25134225

Target pathways

Aggregated over 1 target gene(s): SLC6A2.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
Disease	1	SLC6A2
Transport of small molecules	1	SLC6A2
R-HSA-425366	1	SLC6A2
SLC-mediated transmembrane transport	1	SLC6A2
SLC-mediated transport of neurotransmitters	1	SLC6A2
SLC transporter disorders	1	SLC6A2
Defective SLC6A2 causes orthostatic intolerance (OI)	1	SLC6A2
Disorders of transmembrane transporters	1	SLC6A2

Dominant GO biological processes

GO term	Targets
neurotransmitter transport	1
amino acid transport	1
chemical synaptic transmission	1
response to xenobiotic stimulus	1
obsolete monoamine transport	1
obsolete norepinephrine transport	1
sodium ion transmembrane transport	1
response to pain	1
dopamine uptake involved in synaptic transmission	1
norepinephrine uptake	1
neuron cellular homeostasis	1
transmembrane transport	1
catecholamine uptake	1
neurotransmitter reuptake	1
chloride transmembrane transport	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
obesity disorder	4	MONDO:0011122	EFO:0001073

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888
cocaine dependence	2	MONDO:0005186	EFO:0002610
narcolepsy	2	MONDO:0021107	MONDO:0016158

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000277	PHASE2	COMPLETED	Mazindol for Cocaine Abuse - 2
NCT02808104	PHASE2	COMPLETED	Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT05055024	PHASE2	COMPLETED	An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

486 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
AMITRIPTYLINE	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2
DACOMITINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2
PIMAVANSERIN	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2
TAFENOQUINE	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2
UMECLIDINIUM	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2
VORAPAXAR	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	SLC6A2
ALECTINIB	ChEMBL	Phase 4 (approved)	SLC6A2
ALFACALCIDOL	ChEMBL	Phase 4 (approved)	SLC6A2
ALFUZOSIN	ChEMBL	Phase 4 (approved)	SLC6A2
AMBENONIUM	ChEMBL	Phase 4 (approved)	SLC6A2
AMINOCAPROIC ACID	ChEMBL	Phase 4 (approved)	SLC6A2
AMIODARONE	ChEMBL	Phase 4 (approved)	SLC6A2
AMLODIPINE	ChEMBL	Phase 4 (approved)	SLC6A2
AMODIAQUINE	ChEMBL	Phase 4 (approved)	SLC6A2
AMOXAPINE	ChEMBL	Phase 4 (approved)	SLC6A2
AMPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2
ASENAPINE	ChEMBL	Phase 4 (approved)	SLC6A2
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	SLC6A2
ATOMOXETINE	ChEMBL	Phase 4 (approved)	SLC6A2
ATRACURIUM	ChEMBL	Phase 4 (approved)	SLC6A2
AZELASTINE	ChEMBL	Phase 4 (approved)	SLC6A2
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	SLC6A2
BENFLUOREX	ChEMBL	Phase 4 (approved)	SLC6A2
BENOXINATE	ChEMBL	Phase 4 (approved)	SLC6A2
BENPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A2
BENZIODARONE	ChEMBL	Phase 4 (approved)	SLC6A2
BENZPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
BENZTROPINE	ChEMBL	Phase 4 (approved)	SLC6A2
BENZYDAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
BENZYL BENZOATE	ChEMBL	Phase 4 (approved)	SLC6A2
BEPRIDIL	ChEMBL	Phase 4 (approved)	SLC6A2
BEXAROTENE	ChEMBL	Phase 4 (approved)	SLC6A2
BITHIONOL	ChEMBL	Phase 4 (approved)	SLC6A2
BOSUTINIB	ChEMBL	Phase 4 (approved)	SLC6A2
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2
BROMHEXINE	ChEMBL	Phase 4 (approved)	SLC6A2
BROMODIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
BROMPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A2
BROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
BUPROPION	ChEMBL	Phase 4 (approved)	SLC6A2
BUTENAFINE	ChEMBL	Phase 4 (approved)	SLC6A2
CABERGOLINE	ChEMBL	Phase 4 (approved)	SLC6A2
CALCIPOTRIENE	ChEMBL	Phase 4 (approved)	SLC6A2
CALCITRIOL	ChEMBL	Phase 4 (approved)	SLC6A2
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	SLC6A2
CANNABIDIOL	ChEMBL	Phase 4 (approved)	SLC6A2
CARBINOXAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
CARVEDILOL	ChEMBL	Phase 4 (approved)	SLC6A2
CASPOFUNGIN	ChEMBL	Phase 4 (approved)	SLC6A2
CELECOXIB	ChEMBL	Phase 4 (approved)	SLC6A2
CETIRIZINE	ChEMBL	Phase 4 (approved)	SLC6A2
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	SLC6A2
CHLOROXINE	ChEMBL	Phase 4 (approved)	SLC6A2
CHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
CHLORPHENTERMINE	ChEMBL	Phase 4 (approved)	SLC6A2
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	SLC6A2
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	SLC6A2
CINACALCET	ChEMBL	Phase 4 (approved)	SLC6A2
CINNARIZINE	ChEMBL	Phase 4 (approved)	SLC6A2
CITALOPRAM	ChEMBL	Phase 4 (approved)	SLC6A2
CLEMASTINE	ChEMBL	Phase 4 (approved)	SLC6A2
CLIOQUINOL	ChEMBL	Phase 4 (approved)	SLC6A2
CLOMIPHENE	ChEMBL	Phase 4 (approved)	SLC6A2
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2
CLOZAPINE	ChEMBL	Phase 4 (approved)	SLC6A2
COBIMETINIB	ChEMBL	Phase 4 (approved)	SLC6A2
COCAINE	ChEMBL	Phase 4 (approved)	SLC6A2
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	SLC6A2
CYCLOFENIL	ChEMBL	Phase 4 (approved)	SLC6A2
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	SLC6A2
DABIGATRAN ETEXILATE	ChEMBL	Phase 4 (approved)	SLC6A2
DANAZOL	ChEMBL	Phase 4 (approved)	SLC6A2
DASATINIB	ChEMBL	Phase 4 (approved)	SLC6A2
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	SLC6A2
DEBRISOQUIN	ChEMBL	Phase 4 (approved)	SLC6A2
DELAMANID	ChEMBL	Phase 4 (approved)	SLC6A2
DEQUALINIUM	ChEMBL	Phase 4 (approved)	SLC6A2
DESIPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
DESLORATADINE	ChEMBL	Phase 4 (approved)	SLC6A2
DESOGESTREL	ChEMBL	Phase 4 (approved)	SLC6A2
DESVENLAFAXINE	ChEMBL	Phase 4 (approved)	SLC6A2
DEXBROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
DEXMEDETOMIDINE	ChEMBL	Phase 4 (approved)	SLC6A2
DEXTROAMPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
DEXTROMETHORPHAN	ChEMBL	Phase 4 (approved)	SLC6A2
DIBENZEPIN	ChEMBL	Phase 4 (approved)	SLC6A2
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	SLC6A2
DIMENHYDRINATE	ChEMBL	Phase 4 (approved)	SLC6A2
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
DIPHENYLPYRALINE	ChEMBL	Phase 4 (approved)	SLC6A2
DISULFIRAM	ChEMBL	Phase 4 (approved)	SLC6A2
DOBUTAMINE	ChEMBL	Phase 4 (approved)	SLC6A2
DOMPERIDONE	ChEMBL	Phase 4 (approved)	SLC6A2

Genes: SLC6A2
Indicated for: obesity disorder
In clinical trials for: attention deficit-hyperactivity disorder, cocaine dependence, narcolepsy
Drugs: Amitriptyline, Crizotinib, Dacomitinib, Pimavanserin, Regorafenib, Tafenoquine, Umeclidinium, Vorapaxar, Acetophenazine, Alectinib, Alfacalcidol, Alfuzosin, Ambenonium, Aminocaproic Acid, Amiodarone, Amlodipine, Amodiaquine, Amoxapine, Amphetamine, Aripiprazole, Asenapine, Astemizole, Atomoxetine, Atracurium, Azelastine, Bazedoxifene, Benfluorex, Benoxinate, Benperidol, Benziodarone, Benzphetamine, Benztropine, Benzydamine, Benzyl Benzoate, Bepridil, Bexarotene, Bithionol, Bosutinib, Brexpiprazole, Bromhexine, Bromodiphenhydramine, Bromperidol, Brompheniramine, Bupropion, Butenafine, Cabergoline, Calcipotriene, Calcitriol, Candesartan Cilexetil, Cannabidiol, Carbinoxamine, Carvedilol, Caspofungin, Celecoxib, Cetirizine, Chlorhexidine, Chloroxine, Chlorpheniramine, Chlorphentermine, Chlorpromazine, Chlorprothixene, Cinacalcet, Cinnarizine, Citalopram, Clemastine, Clioquinol, Clomiphene, Clomipramine, Clotrimazole, Clozapine, Cobimetinib, Cocaine, Cyclobenzaprine, Cyclofenil, Cyproheptadine, Dabigatran Etexilate, Danazol, Dasatinib, Daunorubicin, Debrisoquin, Delamanid, Dequalinium, Desipramine, Desloratadine, Desogestrel, Desvenlafaxine, Dexbrompheniramine, Dexmedetomidine, Dextroamphetamine, Dextromethorphan, Dibenzepin, Diethylstilbestrol, Dimenhydrinate, Diphenhydramine, Diphenylpyraline, Disulfiram, Dobutamine, Domperidone

Summary

Identifiers

Drug identity and classification

Targets

Targets

Bioactivity

Target pathways

Top Reactome pathways

Dominant GO biological processes

Indications & clinical

Indications

Clinical trials

Phase distribution

Top trials by phase / activity

Clinical evidence (CIViC)

Pharmacology

Pharmacogenomics

Related molecules

Related molecules

Related Atlas pages